Page 85 - Read Online

Page 261 Nickoloff et al. Cancer Drug Resist 2021;4:244-63 I http://dx.doi.org/10.20517/cdr.2020.89

161. Balbous A, Cortes U, Guilloteau K, et al. A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells. BMC Cancer
2016;16:604.
162. King HO, Brend T, Payne HL, et al. RAD51 Is a selective DNA repair target to radiosensitize glioma stem cells. Stem Cell Reports
2017;8:125-39.
163. Pastushok L, Fu Y, Lin L, et al. A novel cell-penetrating antibody fragment inhibits the DNA repair protein RAD51. Sci Rep
2019;9:11227.
164. Turchick A, Liu Y, Zhao W, Cohen I, Glazer PM. Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient
melanoma and glioma cells. Oncotarget 2019;10:1272-83.
165. Turchick A, Hegan DC, Jensen RB, Glazer PM. A cell-penetrating antibody inhibits human RAD51 via direct binding. Nucleic Acids Res
2017;45:11782-99.
166. Cyteir Therapeutics I. A phase 1/2 study of CYT-0851, an oral RAD51 inhibitor, in B-cell malignancies and advanced solid tumors. In;
2019.
167. Yu D, Sekine E, Fujimori A, Ochiya T, Okayasu R. Down regulation of BRCA2 causes radio-sensitization of human tumor cells in vitro
and in vivo. Cancer Sci 2008;99:810-5.
168. Hirai T, Shirai H, Fujimori H, et al. Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high
linear energy transfer radiation. Cancer Sci 2012;103:1045-50.
169. Hirai T, Saito S, Fujimori H, et al. Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells. Biochem Biophys Res
Commun 2016;478:234-40.
170. Jannetti SA, Zeglis BM, Zalutsky MR, Reiner T. Poly(ADP-ribose)polymerase (PARP) inhibitors and radiation therapy. Front Pharmacol
2020;11:170.
171. Chang L, Graham PH, Hao J, et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells
through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis 2014;5:e1437.
172. Schotz U, Balzer V, Brandt FW, et al. Dual PI3K/mTOR inhibitor NVP-BEZ235 enhances radiosensitivity of head and neck squamous
cell carcinoma (HNSCC) cell lines due to suppressed double-strand break (DSB) repair by non-homologous end joining. Cancers
2020;12:467.
173. Gil del Alcazar CR, Hardebeck MC, Mukherjee B, et al. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor
NVP-BEZ235 as a strategy for radiosensitization of glioblastoma. Clin Cancer Res 2014;20:1235-48.
174. Hirakawa H, Fujisawa H, Masaoka A, et al. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective
tumor control in human lung cancer cells. Cancer Med 2015;4:426-36.
175. Lee Y, Li HK, Masaoka A, et al. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting
DNA repair by homologous recombination and non-homologous end joining. Radiother Oncol 2016;121:162-8.
176. Noguchi M, Yu D, Hirayama R, et al. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90
inhibitor 17-allylamino-17-demethoxygeldanamycin. Biochem Biophys Res Commun 2006;351:658-63.
177. Segawa T, Fujii Y, Tanaka A, et al. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Int J Mol Med 2014;33:559-64.
178. Lee Y, Sunada S, Hirakawa H, et al. TAS-116, a novel Hsp90 inhibitor, selectively enhances radiosensitivity of human cancer cells to
X-rays and carbon ion radiation. Mol Cancer Ther 2017;16:16-24.
179. Fujii Y, Kato T, Kubota N, et al. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor
17-allylamino-17-demethoxygeldanamycin. Oncol Rep 2010;23:199-203.
180. Shimomura A, Yamamoto N, Kondo S, et al. First-in-human Phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced
solid tumors. Mol Cancer Ther 2019;18:531-40.
181. Vormoor B, Schlosser YT, Blair H, et al. Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes
DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2. Oncotarget 2017;8:113418-30.
182. Fok JHL, Ramos-Montoya A, Vazquez-Chantada M, et al. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation,
chemotherapy and olaparib activity. Nat Commun 2019;10:5065.
183. Zhang Q, Green MD, Lang X, et al. Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune
checkpoint blockade therapy. Cancer Res 2019;79:3940-51.
184. Chen BP, Uematsu N, Kobayashi J, et al. Ataxia telangiectasia mutated (ATM) is essential for DNA-PKcs phosphorylations at the Thr-
2609 cluster upon DNA double strand break. J Biol Chem 2007;282:6582-7.
185. Cornell L, Munck JM, Alsinet C, et al. DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response
to treatment and survival. Clin Cancer Res 2015;21:925-33.
186. Abdel-Fatah TM, Arora A, Moseley P, et al. ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial
ovarian cancers. BBA Clin 2014;2:10-7.
187. Toulany M, Maier J, Iida M, et al. Akt1 and Akt3 but not Akt2 through interaction with DNA-PKcs stimulate proliferation and post-
irradiation cell survival of K-RAS-mutated cancer cells. Cell Death Discov 2017;3:17072.
188. Baptistella AR, Landemberger MC, Dias MVS, et al. Rab5C enhances resistance to ionizing radiation in rectal cancer. J Mol Med
2019;97:855-69.
189. Zou M, Li Y, Xia S, et al. Knockdown of CAVEOLIN-1 sensitizes human basal-like triple-negative breast cancer cells to radiation. Cell
Physiol Biochem 2017;44:778-91.
190. Saki M, Makino H, Javvadi P, et al. EGFR mutations compromise hypoxia-associated radiation resistance through impaired replication